Sprint Bioscience AB (publ) (STO:SPRINT)

Market Cap	360.86M +755.7%
Revenue (ttm)	153.10M +144.6%
Net Income	84.49M
EPS	0.82
Shares Out	105.52M
PE Ratio	4.15
Forward PE	11.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,426
Average Volume	601,065
Open	3.400
Previous Close	3.420
Day's Range	3.400 - 3.560
52-Week Range	0.391 - 4.210
Beta	-0.52
RSI	52.55
Earnings Date	May 15, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 30
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPRINT